Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis.
CONCLUSIONS: Rituximab had a beneficial effect and remissions of proteinuria on MN during follow-up times, but some adverse events were still unknown. Taking consideration of long-term therapeutic side effects and dose of the drug, we suggest that rituximab might replace cyclophosphamide and steroids as first-line immunosuppressive therapy in MN patients.
PMID: 30536351 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Computers | Databases & Libraries | Drugs & Pharmacology | Nephrotic Syndrome | Proteinuria | Rituxan | Science | Study